Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R2D2: Trastuzumab and Pertuzumab with Docetaxel in HER2-mutated NSCLC
NCT03845270Phase 2Completed
- Sponsor
- IFCT
- Start
- May 2019
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pertuzumab in non-small cell lung cancer (NSCLC), sponsored by IFCT. Primary endpoint: Overall Response Rate at 24 months. Started May 2019; status: completed.
02
Drugs
pertuzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03845270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03845270.